Long-term management of Parkinson’s disease using levodopa combinations

References

• Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson’s disease. J Neural Transm Suppl. 1999;56:31–74.
   PubMedGoogle Scholar
• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm. 2004;111:201–216.
   PubMed Web of Science ®Google Scholar
• Foley P, Mizuno Y, Nagatsu T, et al. The L-DOPA story - an early Japanese contribution. Parkinsonism Relat Disord. 2000;6:1–1.
   Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39.
   PubMed Web of Science ®Google Scholar
• Camargo SM, Vuille-dit-Bille RN, Mariotta L, et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson’s disease. J Pharmacol Exp Ther. 2014;351:114–123.
   PubMed Web of Science ®Google Scholar
• Hill-Burns EM, Debelius JW, Morton JT, et al. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32:739–749.
   PubMed Web of Science ®Google Scholar
• Qian Y, Yang X, Xu S, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain Behav Immun. 2018;70:194–202.
   PubMed Web of Science ®Google Scholar
• Scheperjans F. Gut microbiota, 1013 new pieces in the Parkinson’s disease puzzle. Curr Opin Neurol. 2016;29:773–780.
   PubMed Web of Science ®Google Scholar
• Muhlack S, Woitalla D, Welnic J, et al. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease. Neurosci Lett. 2004;363:284–287.
   PubMed Web of Science ®Google Scholar
• Müller T. Motor complications, levodopa metabolism and progression of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2011;7:847–855.
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Pietroiusti A, Galante A, et al. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson’s disease patients. Ann Neurol. 2001;50:686–687.
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Pietroiusti A, Sancesario G, et al. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease patients. Neurol Sci. 2001;22:89–91.
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr. 2001;113:851–854.
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. Experimental treatment of parkinsonism with L-Dopa. Neurology. 1968;18:276–277.
   PubMed Web of Science ®Google Scholar
• Ciesielska A, Samaranch L, San SW, et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS One. 2017;12:e0169965.
   PubMed Web of Science ®Google Scholar
• Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75:157–174.
   PubMed Web of Science ®Google Scholar
• Aquilonius SM, Nyholm D. Development of new levodopa treatment strategies in Parkinson’s disease-from bedside to bench to bedside. Ups J Med Sci. 2017;122:71–77.
   PubMed Web of Science ®Google Scholar
• Calabresi P, Di FM, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9:1106–1117.
   PubMed Web of Science ®Google Scholar
• Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol. 2010;257:S268–S275.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol. 2017;74:941–949.
   PubMed Web of Science ®Google Scholar
• Johnston TH, Fox SH, McIldowie MJ, et al. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson’s disease. J Pharmacol Exp Ther. 2010;333:865–873.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord. 2014;20(9):947–956.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179–186.
   PubMed Web of Science ®Google Scholar
• Gregoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19:508–514.
   PubMed Web of Science ®Google Scholar
• Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368:610–622.
   PubMed Web of Science ®Google Scholar
• Verhagen ML, Del DP. van den MP, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease Neurol. 1998;50:1323–1326.
   PubMed Web of Science ®Google Scholar
• Auffret M, Le JF, Maurus A, et al. Apomorphine pump in advanced Parkinson’s disease: effects on motor and nonmotor symptoms with brain metabolism correlations. J Neurol Sci. 2017;372:279–287.
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:96–101.
   PubMed Web of Science ®Google Scholar
• Senek M, Nyholm D. Continuous drug delivery in Parkinson’s disease. CNS Drugs. 2014;28:19–27.
   PubMed Web of Science ®Google Scholar
• Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. The CR first study group. Eur Neurol. 1997;37:23–27.
   PubMed Web of Science ®Google Scholar
• Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand. 1996;93:14–20.
   PubMed Web of Science ®Google Scholar
• Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68:589–594.
   PubMed Web of Science ®Google Scholar
• Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary((R)), an extended-release capsule formulation of carbidopa-levodopa. Clin Pharmacokinet. 2017;56:999–1014.
   PubMed Web of Science ®Google Scholar
• Kianirad Y, Simuni T. Novel approaches to optimization of levodopa therapy for Parkinson’s disease. Curr Neurol Neurosci Rep. 2016;16:34.
   PubMed Web of Science ®Google Scholar
• Chen C, Cowles VE, Sweeney M, et al. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:67–72.
   PubMed Web of Science ®Google Scholar
• Dorozynski P, Kulinowski P, Mendyk A, et al. Gastroretentive drug delivery systems with L-dopa based on carrageenans and hydroxypropylmethylcellulose. Int J Pharm. 2011;404:169–175.
   PubMed Web of Science ®Google Scholar
• Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson’s disease. CNS Drugs. 2016;30:1079–1095.
   PubMed Web of Science ®Google Scholar
• Klausner EA, Lavy E, Barta M, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res. 2003;20:1466–1473.
   PubMed Web of Science ®Google Scholar
• Verhagen ML, Stover N, Chen C, et al. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov Disord. 2015;30:1222–1228.
   PubMedGoogle Scholar
• Lewitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov Disord. 2014;29:75–82.
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Bomelburg M, et al. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord. 2012;27:1704–1705.
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Müller T, et al. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm (Vienna). 2012;119:369–372.
   PubMed Web of Science ®Google Scholar
• Ramot Y, Nyska A, Maronpot RR, et al. Ninety-day local tolerability and toxicity study of Nd0612, a novel formulation of levodopa/carbidopa, administered by subcutaneous continuous infusion in minipigs. Toxicol Pathol. 2017;45:764–773.
   PubMed Web of Science ®Google Scholar
• Malek N, Grosset DG. Medication adherence in patients with Parkinson’s disease. CNS Drugs. 2015;29:47–53.
   PubMed Web of Science ®Google Scholar
• Hinz M, Stein A, Cole T. The Parkinson’s disease death rate: carbidopa and vitamin B6. Clin Pharmacol. 2014;6:161–169.
   PubMedGoogle Scholar
• Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci (Lond). 1979;56:89–93.
   PubMed Web of Science ®Google Scholar
• Skodda S, Müller T. Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa(R) therapy. J Neural Transm (Vienna). 2013;120:315–318.
   PubMed Web of Science ®Google Scholar
• Müller T, Kohlhepp W. Hypomethylation in Parkinson’s disease: an epigenetic drug effect? Mov Disord. 2016;31:605–607.
   PubMedGoogle Scholar
• Taravini IR, Larramendy C, Gomez G, et al. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson’s disease. Neuropharmacology. 2016;101:576–589.
   PubMed Web of Science ®Google Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13:707–718.
   PubMed Web of Science ®Google Scholar
• Feng LR, Maguire-Zeiss KA. Dopamine and paraquat enhance alpha synuclein-induced alterations in membrane conductance. Neurotox Res. 2011;20:387–401.
   PubMed Web of Science ®Google Scholar
• Hashim HZ, Wan Musa WR, Ngiu CS, et al. Parkinsonism complicating acute organophosphate insecticide poisoning. Ann Acad Med Singapore. 2011;40:150–151.
   PubMed Web of Science ®Google Scholar
• Moisan F, Spinosi J, Dupupet JL, et al. The relation between type of farming and prevalence of Parkinson’s disease among agricultural workers in five French districts. Mov Disord. 2011;26:271–279.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry. 1995;58:293–299.
   PubMed Web of Science ®Google Scholar
• Müller T, Muhlack S. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients. J Neural Transm (Vienna). 2014;121:643–648.
   PubMed Web of Science ®Google Scholar
• Demicheva E, Cui YF, Bardwell P, et al. Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. Cell Rep. 2015;10:1887–1898.
   PubMed Web of Science ®Google Scholar
• Müller T, Trommer I, Muhlack S, et al. Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm (Vienna). 2016;123:401–406.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653–1661.
   PubMed Web of Science ®Google Scholar
• Fahn S. Levodopa in the treatment of Parkinson’s disease. J Neural Transm Suppl. 2006;71:1–15.
   Google Scholar
• Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12:747–755.
   PubMed Web of Science ®Google Scholar
• Clarke CE. A “cure” for Parkinson’s disease: can neuroprotection be proven with current trial designs? Mov Disord. 2004;19:491–498.
   PubMed Web of Science ®Google Scholar
• Morrish P. Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord. 2002;17:229–232.
   PubMed Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016;8:360ra136.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Grasmeijer F, Hagedoorn P, et al. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur J Pharm Biopharm. 2015;97:22–29.
   PubMed Web of Science ®Google Scholar
• Witjas T, Eusebio A, Fluchere F, et al. Addictive behaviors and Parkinson’s disease. Rev Neurol (Paris). 2012;168:624–633.
   PubMed Web of Science ®Google Scholar
• Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6:141–150.
   PubMed Web of Science ®Google Scholar
• Liedhegner EA, Steller KM, Mieyal JJ. Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson’s disease. Chem Res Toxicol. 2011;24:1644–1652.
   PubMed Web of Science ®Google Scholar
• Gdynia HJ, Müller T, Sperfeld AD, et al. Severe sensorimotor neuropathy after intake of highest dosages of vitamin B6. Neuromuscul Disord. 2008;18:156–158.
   PubMed Web of Science ®Google Scholar
• Scott K, Zeris S, Kothari MJ. Elevated B6 levels and peripheral neuropathies. Electromyogr Clin Neurophysiol. 2008;48:219–223.
   PubMedGoogle Scholar
• Van HF, Van De KS, Van PE, et al. Vitamin B6 in health supplements and neuropathy: case series assessment of spontaneously reported cases. Drug Saf. 2018. doi: 10.1007/s40264-018-0664-0. [Epub ahead of print]
   Google Scholar
• Vrolijk MF, Opperhuizen A, Jansen EHJM, et al. The vitamin B6 paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicol In Vitro. 2017;44:206–212.
   PubMed Web of Science ®Google Scholar
• Müller T, Jugel C, Ehret R, et al. Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel. J Neural Transm (Vienna). 2011;118:1329–1333.
   PubMed Web of Science ®Google Scholar
• Martino T, Melchionda D, Tonti P, et al. Weight loss and decubitus duodenal ulcer in Parkinson’s disease treated with levodopa-carbidopa intestinal gel infusion. J Neural Transm (Vienna). 2016;123:1395–1398.
   PubMed Web of Science ®Google Scholar
• Udd M, Lyytinen J, Eerola-Rautio J, et al. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease. Brain Behav. 2017;7:e00737.
   PubMed Web of Science ®Google Scholar
• Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: A randomized crossover study. Mov Disord. 2017;32:283–286.
   PubMed Web of Science ®Google Scholar
• Agundez JA, Garcia-Martin E, onso-Navarro H, et al. Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 2013;9:859–874.
   PubMed Web of Science ®Google Scholar